雙合式支架血管，胸主动脉病灶治療
PMA 核准號：P210006 · 2026-09-08
廣告
器材摘要
Hybrid stent graft, thoracic aortic lesion treatment is the device name listed in this FDA 510(k) record. The listed applicant is Vascutek, Ltd.. It received FDA 510(k) clearance on 2026-09-08. The device is classified under product code QSK. It was reviewed by the CV advisory panel.
常見問題
What is the Hybrid stent graft, thoracic aortic lesion treatment?
Hybrid stent graft, thoracic aortic lesion treatment is a medical device that received FDA 510(k) clearance on 2026-09-08. The listed applicant is Vascutek, Ltd..
When did Hybrid stent graft, thoracic aortic lesion treatment receive FDA 510(k) clearance?
The clearance date for Hybrid stent graft, thoracic aortic lesion treatment can be found in the official FDA records.
Who is the listed applicant for Hybrid stent graft, thoracic aortic lesion treatment?
The FDA 510(k) record lists Vascutek, Ltd. as the applicant. This does not by itself establish the device manufacturer.
What is the FDA product code for Hybrid stent graft, thoracic aortic lesion treatment?
The FDA product code for Hybrid stent graft, thoracic aortic lesion treatment is QSK.
相關臨床試驗
相關紀錄係使用名稱、產品代碼或其他後設資料自動配對。配對結果並不構成已驗證的臨床、科學、企業或監管關係，請查閱連結的官方來源。
官方來源
在 FDA 資料庫中查看 →資料來源為 FDA Open API。如需最新且權威的資訊，請始終參閱官方記錄。
廣告